pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression

[1] Squadroni M(2010)Chemotherapy in pancreatic adenocarcinoma Eur Rev Med Pharmacol Sci. 14 386-3894

[2] Fazio N(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol. 15 2403-13

[3] Burris HA(1996)A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer Ann Oncol. 7 347-53

[4] Moore MJ(1999)Current chemotherapeutic possibilities in pancreaticobiliary cancer Ann Oncol. 10 S157-61

[5] Anderson J(1999)Experimental drugs and drug combinations in pancreatic cancer Ann Oncol. 10 S234-8

[6] Rothenberg ML(2003)Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death Oncogene. 22 3243-51

[7] Moore MJ(2006)Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma Ann Surg Oncol 13 933-9

[8] Cripps MC(2013)ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells J Int Med Res. 41 300-6

[9] van Riel JMGH(2010)The biochemistry of apoptosis Nature. 407 770-6

[10] van Groeningen CJ(2000)Role of the BH3 (bcl-2 homology 3) domain in the regulation of apoptosis and bcl-2-related proteins Biochem Soc Trans. 28 51-6

[1] Squadroni M(2010)Chemotherapy in pancreatic adenocarcinoma Eur Rev Med Pharmacol Sci. 14 386-3894

[2] Fazio N(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol. 15 2403-13

[3] Burris HA(1996)A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer Ann Oncol. 7 347-53

[4] Moore MJ(1999)Current chemotherapeutic possibilities in pancreaticobiliary cancer Ann Oncol. 10 S157-61

[5] Anderson J(1999)Experimental drugs and drug combinations in pancreatic cancer Ann Oncol. 10 S234-8

[6] Rothenberg ML(2003)Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death Oncogene. 22 3243-51

[7] Moore MJ(2006)Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma Ann Surg Oncol 13 933-9

[8] Cripps MC(2013)ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells J Int Med Res. 41 300-6

[9] van Riel JMGH(2010)The biochemistry of apoptosis Nature. 407 770-6

[10] van Groeningen CJ(2000)Role of the BH3 (bcl-2 homology 3) domain in the regulation of apoptosis and bcl-2-related proteins Biochem Soc Trans. 28 51-6